Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director · Chief Executive Officer | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 157,316 |
Reported balance
After 2026-08-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-07 · Sale · Disposed 17,000 · Balance 157,316 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026. F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: This amount includes 138,049 unvested RSUs subject to each grant's vesting schedule as previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2019 Filed Aug 12, 2019 14:37 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,175 | $6.06 | $7,115.80 |
DisclosureSEC source: 0001209191-19-045444 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,360 Read SEC document |
| May 13, 2019 Filed May 14, 2019 13:47 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 995 | $6.99 | $6,954.85 |
DisclosureSEC source: 0001209191-19-029514 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,185 Read SEC document |
| March 14, 2019 Filed Mar 14, 2019 15:25 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,530 | $6.49 | $9,929.70 |
DisclosureSEC source: 0001209191-19-019345 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,190 Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 21:59 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 565,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001209191-19-004579 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,000 Underlying: Common Stock · 565,000 shares Expires 2029-01-18 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020. Read SEC document |
| May 15, 2018 Filed May 16, 2018 12:46 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,725 | $5.85 | $10,091.25 |
DisclosureSEC source: 0001209191-18-030366 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,660 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 13:48 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,160 | $6.89 | $7,986.60 |
DisclosureSEC source: 0001209191-18-019757 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,935 Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 22:27 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 437,500 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-18-002512 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2028-01-04 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 13:59 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,000 | $7.17 | $7,168.50 |
DisclosureSEC source: 0001209191-17-060145 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,775 Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 17:17 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,695 | $6.00 | $10,170.00 |
DisclosureSEC source: 0001209191-17-048535 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,775 Read SEC document |
| May 11, 2017 Filed May 12, 2017 13:03 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 3,250 | $6.01 | $19,539.00 |
DisclosureSEC source: 0001209191-17-031700 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,080 Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 11:58 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionOptions to purchase common stock · Derivative | 20,000 | $1.00 Strike: $1.00 | $20,000.00 |
DisclosureSEC source: 0001209191-17-021246 · doc4.xml · derivative · entry 2 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,728 Underlying: Common stock · 20,000 shares Expires 2024-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 17, 2017 11:58 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | Exercise / conversionCommon Stock | 20,000 | $1.00 | $20,000.00 |
DisclosureSEC source: 0001209191-17-021246 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 21:17 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 377,500 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-17-017470 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,500 Underlying: Common Stock · 377,500 shares Expires 2027-03-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 16:44 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,340 | $7.64 | $10,237.60 |
DisclosureSEC source: 0001209191-16-151867 · doc4.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,830 Read SEC document |
| November 22, 2016 Filed Jan 20, 2017 22:28 UTC Amendment | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,340 | $7.64 | $10,237.60 |
DisclosureSEC source: 0001209191-17-004954 · doc4a.xml · nonDerivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,830 F1 · balance_after: This amendment is being filed solely for the purpose of correcting the number of securities reported in Box 5 to Table 1 to indicate the number of securities beneficially owned following the transaction. Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 20:50 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 150,000 | $0.00 Strike: $8.71 | $0.00 |
DisclosureSEC source: 0001209191-16-145413 · doc4.xml · derivative · entry 1 Cohen Yuval · CIK 0001626003 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-10-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on October 6, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.